Additional file 2: of Changes in risk perceptions during the 2014 Ebola virus disease epidemic: results of two consecutive surveys among the general population in Lower Saxony, Germany

Differences in 2014’s risk perception between individuals who responded to both surveys and individuals who responded to the first survey only (PDF 209 kb

Kaplan-Meier plot displaying survival after stroke in patients with and without beta-blocker therapy.

<p>Patients with beta blocker therapy showed a higher 30 days mortality than those without beta blocker therapy in the univariable (log-rank test, p = 0.003) and multivariable analyses (Cox regression model, p = 0.006).</p

Effect of beta-blocker therapy on post-stroke infections stratified by statin therapy.

<p>*p-value for interaction based on a Likelihood Ratio Test comparing a model with interaction term with the corresponding model without interaction term</p><p>Effect of beta-blocker therapy on post-stroke infections stratified by statin therapy.</p

Post-stroke pneumonia, urinary tract infection and mortality in patients with and without beta-blocker therapy (n = 625).

<p>HR/RR: Hazard-Ratio and Rate Ratio (adjusted for age, sex and baseline NIHSS) obtained using Poisson (pneumonia, urinary tract infection) and Cox (death) regression models, CI: Confidence interval,</p><p>*Likelihood Ratio Test,</p><p>‡ competing risk situation</p><p>Post-stroke pneumonia, urinary tract infection and mortality in patients with and without beta-blocker therapy (n = 625).</p

C-reactive protein, leukocyte count, NIHSS, modified ranking scale and Barthel-index in patients with and without beta-blocker therapy (n = 625).

<p>NIHSS: National Institute of Health Stroke Scale; CRP: C-reactive protein; mRS: modified Ranking Scale; SE: Standard error; ANCOVAs adjusted for age, sex, baseline NIHSS and individual follow-up; Change in outcome parameters were calculated as follows: baseline value—follow-up value (for NIHSS) or highest value—baseline value (for CRP and leukocyte count)</p><p>C-reactive protein, leukocyte count, NIHSS, modified ranking scale and Barthel-index in patients with and without beta-blocker therapy (n = 625).</p

Baseline characteristics of patients with and without beta-blocker therapy (n = 625).

<p>SD: Standard deviation, IQR: Interquartile range,</p><p>*t-tests, Wilcoxon rank-sum tests and chi-square tests as appropriate</p><p>Baseline characteristics of patients with and without beta-blocker therapy (n = 625).</p

Q_Alb values and ApoE genotypes in a population of patients with different types of dementia (n = 520).

<p>Displayed are boxplots (box: interquartile range, line: median) of Q_Alb (non-logarithmised, non-transformed) values dependent on A. ApoE genotypes, B. presence of ApoE E4 alleles (dominant genetic model with E4 as risk allele), C. number of ApoE E4 alleles (0, 1 or 2, additive genetic model with E4 as risk allele), D. presence of ApoE E3 alleles (dominant genetic model with E3 as risk allele), E. number of ApoE E3 alleles (0, 1 or 2, additive genetic model with E3 as risk allele), F. presence of ApoE E2 alleles (dominant genetic model with E2 as risk allele), G. number of ApoE E2 alleles (0, 1 or 2, additive genetic model with E2 as risk allele). Corresponding summary statistics of logarithmised Q_Alb values can be found in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0084405#pone-0084405-t002" target="_blank">Table 2</a> (A.) and 3 (B., C., D., E., F., G.).</p

Q_Alb^* by ApoE genotype and type of dementia.

<p>*Back-transformed means and 95% confidence intervals of the natural logarithm of Q_Alb.</p><p>**ANCOVA adjusted for age and sex.</p

Q_Alb^* by number of ApoE4, ApoE3, ApoE2 alleles and type of dementia under the assumption of dominant and additive genetic models.

<p>*Back-transformed means and 95% confidence intervals of the natural logarithm of Q_Alb.</p><p>**ANCOVA adjusted for age and sex.</p

Baseline characteristics of study participants by type of dementia.

<p>*Chi square test.</p><p>**ANOVA.</p><p>***Fisher's exact test.</p><p>****Back-transformed means and 95% confidence intervals of the natural logarithm of Q_Alb.</p